Cure My Disease

Don't miss your cure!

 Log in / Sign up

Antibiotic showdown: can tigecycline match older drugs against tough skin infections?

NCT ID NCT00368537

Cure Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

This trial compares the antibiotic tigecycline with two older antibiotics, ampicillin-sulbactam and amoxicillin-clavulanate, in adults with complicated skin or skin structure infections that need intravenous treatment. About 550 participants receive one of the treatments for 4 to 14 days. Researchers measure how many patients are cured at a follow-up visit, tracking safety along the way.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tigecycline, an intravenous antibiotic
What this could lead to
If tigecycline works as well as the older antibiotics, doctors could have another intravenous option for serious skin infections, including those caused by resistant bacteria.
What could go wrong
Tigecycline may not clear infections as reliably as the comparison antibiotics, and it can cause nausea, vomiting, or other side effects. This is a Phase 4 comparison, so it tests an already approved drug rather than a new one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

550 people

The number who actually took part.

Start date

Sep 2006

Finished

Sep 2008

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of complicated skin or skin structure infection * Male or female, 18 years or older * Need for intravenous treatment for 4 to 14 days Exclusion Criteria: * Skin infection that can be treated by surgery \& wound care alone * Diabetic foot ulcers or bedsores where the infection is present longer than 1 week * Poor circulation such that amputation of the infected site is likely within a month Other exclusions apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Skin diseases, bacterial are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cellulitis skin disease caused by bacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Skin diseases, bacterial

Contacts and locations

Locations

  • Study site

    Scottsdale, Arizona, 85251, United States

  • Study site

    Jonesboro, Arkansas, 72401, United States

  • Study site

    Chula Vista, California, 91911, United States

  • Study site

    Mission Viejo, California, 92691, United States

  • Study site

    National City, California, 91950, United States

  • Study site

    Denver, Colorado, 80218, United States

  • Study site

    Washington D.C., District of Columbia, 20017, United States

  • Study site

    Washington D.C., District of Columbia, 20037, United States

  • Study site

    Orlando, Florida, 32803, United States

  • Study site

    Vero Beach, Florida, 32960, United States

  • Study site

    Fort Gordon, Georgia, 30905, United States

  • Study site

    Idaho Falls, Idaho, 83404, United States

  • Study site

    Decatur, Illinois, 62526, United States

  • Study site

    Naperville, Illinois, 60540, United States

  • Study site

    Springfield, Illinois, 62702, United States

  • Study site

    Topeka, Kansas, 66606, United States

  • Study site

    Cambridge, Massachusetts, 02139, United States

  • Study site

    Worcester, Massachusetts, 01655, United States

  • Study site

    Detroit, Michigan, 48202, United States

  • Study site

    Lincoln, Nebraska, 68510, United States

  • Study site

    Hackensack, New Jersey, 07601, United States

  • Study site

    Neptune City, New Jersey, 07754, United States

  • Study site

    Buffalo, New York, 14215, United States

  • Study site

    Elmira, New York, 14905, United States

  • Study site

    New Hyde Park, New York, 11040, United States

  • Study site

    Columbus, Ohio, 43214, United States

  • Study site

    Lima, Ohio, 45801, United States

  • Study site

    Lansdale, Pennsylvania, 19446, United States

  • Study site

    Philadelphia, Pennsylvania, 19140, United States

  • Study site

    Fort Worth, Texas, 76104, United States

  • Study site

    Houston, Texas, 77026, United States

  • Study site

    Winnipeg, Manitoba, R3A 1R9, Canada

  • Study site

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Study site

    Montreal, Quebec, H1T 2M4, Canada

  • Study site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Study site

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • Study site

    Saskatoon, Saskatchewan, S7N 0W8, Canada

  • Study site

    Québec, G1V 4G5, Canada

  • Study site

    Hong Kong, Hong Kong

  • Study site

    Ramat Gan, 52621, Israel

  • Study site

    Beirut, 110 32090, Lebanon

  • Study site

    Pulau Pinang, 10990, Malaysia

  • Study site

    Manila, 1000, Philippines

  • Study site

    Manila, 1014, Philippines

  • Study site

    Singapore, 169608, Singapore

  • Study site

    Cape Town, 7531, South Africa

  • Study site

    Gauteng, 0181, South Africa

  • Study site

    KZ-Natal, 3610, South Africa

  • Study site

    Mpumalanga, 1050, South Africa

  • Study site

    Daejeon, 301-721, South Korea

  • Study site

    Incheon, 405-760, South Korea

  • Study site

    Seoul, 120-752, South Korea

  • Study site

    Seoul, 133-791, South Korea

  • Study site

    Taipei, 220, Taiwan

  • Study site

    Bangkok, 10330, Thailand

  • Study site

    Bangkok, 10400, Thailand

  • Study site

    Bangkok, 10700, Thailand